BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29424887)

  • 1. MiR-205 enhances cisplatin sensitivity of glioma cells by targeting E2F1.
    Li FF; Xing C; Wu LL; Xue F
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):299-306. PubMed ID: 29424887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
    Zheng H; Wang JJ; Yang XR; Yu YL
    World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.
    Chen W; Yang Y; Chen B; Lu P; Zhan L; Yu Q; Cao K; Li Q
    J Neurooncol; 2014 Oct; 120(1):43-53. PubMed ID: 25139024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells.
    Xiao B; Tan L; He B; Liu Z; Xu R
    J Transl Med; 2013 Jul; 11():172. PubMed ID: 23866847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of microRNA-128 on cisplatin resistance of glioma SHG-44 cells by targeting JAG1.
    Yi DY; Su Q; Zhang FC; Fu P; Zhang Q; Cen YC; Zhao HY; Xiang W
    J Cell Biochem; 2018 Apr; 119(4):3162-3173. PubMed ID: 29091297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response.
    Cataldo A; Cheung DG; Balsari A; Tagliabue E; Coppola V; Iorio MV; Palmieri D; Croce CM
    Oncotarget; 2016 Jan; 7(1):786-97. PubMed ID: 26623722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
    Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
    BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mir-338-3p Inhibits Malignant Biological Behaviors of Glioma Cells by Targeting MACC1 Gene.
    Shang C; Hong Y; Guo Y; Xue YX
    Med Sci Monit; 2016 Mar; 22():710-6. PubMed ID: 26936749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of mTOR by miR-107 to facilitate glioma cell apoptosis and to enhance cisplatin sensitivity.
    Su PF; Song SQ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6864-6872. PubMed ID: 30402851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
    Zhou X; Jin W; Jia H; Yan J; Zhang G
    J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1.
    Wu H; Li W; Zhang M; Zhu S; Zhang D; Wang X
    J Cancer Res Ther; 2016 Oct; 12(Supplement):68-71. PubMed ID: 27721258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of miR-141 reverses cisplatin resistance in non-small cell lung cancer cells via upregulation of programmed cell death protein 4.
    Fu WF; Chen WB; Dai L; Yang GP; Jiang ZY; Pan L; Zhao J; Chen G
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2565-72. PubMed ID: 27383306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2.
    Wang T; Ge G; Ding Y; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
    Chin Med J (Engl); 2014; 127(12):2357-62. PubMed ID: 24931256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bufalin Inhibits Cellular Proliferation and Cancer Stem Cell-Like Phenotypes via Upregulation of MiR-203 in Glioma.
    Liu T; Wu C; Weng G; Zhao Z; He X; Fu C; Sui Z; Huang SX
    Cell Physiol Biochem; 2017; 44(2):671-681. PubMed ID: 29169175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
    Liu HJ; Li GL; Lei PC
    Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.
    Chen Q; Qin R; Fang Y; Li H
    Cell Physiol Biochem; 2015; 36(3):956-65. PubMed ID: 26087719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.